|
Category:natural substances and extractives
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Boiling Point: | 432.55 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 386.00 °F. TCC ( 196.60 °C. ) (est)
|
| logP (o/w): | 2.947 (est) |
| Soluble in: |
| | water, 576.7 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
|
Not determined
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | natural substances and extractives |
| Recommendation for urolithin B usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for urolithin B flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| 6H- | dibenzo(b,d)pyran-6-one, 3-hydroxy- | | 6H- | dibenzo[b,d]pyran-6-one, 3-hydroxy- | | 3- | hydroxy-6H-benzo[c]chromen-6-one | | 3- | hydroxy-benzo[c]chromen-6-one | | 3- | hydroxybenzo[c]chromen-6-one |
Articles:
| PubMed:Gastrointestinal stability of urolithins: an in vitro approach. |
| PubMed:Chemopreventive activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon cancer cells. |
| PubMed:Preparative isolation and purification of urolithins from the intestinal metabolites of pomegranate ellagitannins by high-speed counter-current chromatography. |
| PubMed:Pilot walnut intervention study of urolithin bioavailability in human volunteers. |
| PubMed:Pomegranate phenolics inhibit formation of advanced glycation endproducts by scavenging reactive carbonyl species. |
| PubMed:Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells. |
| PubMed:Influence of gut microbiota-derived ellagitannins' metabolites urolithins on pro-inflammatory activities of human neutrophils. |
| PubMed:Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. |
| PubMed:Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials. |
| PubMed:Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. |
| PubMed:Urolithins display both antioxidant and pro-oxidant activities depending on assay system and conditions. |
| PubMed:Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. |
| PubMed:In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. |
| PubMed:Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells. |
| PubMed:Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. |
| PubMed:Metabolism of oak leaf ellagitannins and urolithin production in beef cattle. |
| PubMed:Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. |
| PubMed:Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. |
| PubMed:Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. |
| PubMed:Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. |
| PubMed:Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. |
| PubMed:A concise synthesis of glucuronide metabolites of urolithin-B, resveratrol, and hydroxytyrosol. |
| PubMed:Dissimilar in vitro and in vivo effects of ellagic acid and its microbiota-derived metabolites, urolithins, on the cytochrome P450 1A1. |
| PubMed:Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. |
| PubMed:Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. |
| PubMed:Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. |
| PubMed:Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. |
| PubMed:Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. |
| PubMed:Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. |
|
3D/inchi